Biotech small-cap CytRx is
getting a lot of attention lately – stemming from positive top-line results of
its phase 2b study of lead candidate aldoxorubicin, as well as from a more than
three-month bull-run of the company’s stock. Wall St. Cheat Sheet contributing
writer Matt Levy is the latest of several market writers to highlight the
CytRx’s achievements and market potential.
To read the full article
visit: http://wallstcheatsheet.com/stocks/good-news-continues-to-roll-in-for-cytrx.html/
Levy starts his recent
article on CytRx by noting the stock’s triple-digit gains following the CytRx’s
phase 2b trial results in which aldoxorubicin demonstrated superiority over
current standard of care chemotherapeutic agent, doxorubicin.
“The news was extremely
positive and investors have become big believers in both the company and the
science. The upward momentum continued on January 8 when the company reported
additional analyses from the Phase 2b trial in STS. When trying to analyze data,
one of the more important components to look at is the hazard ratio. In the
case of aldoxorubicin, the hazard ratio allows doctors to determine the
likelihood that tumor progression will be reached during a specified period.
Hazard ratios less than 1 indicate that there is a substantial benefit of
aldoxorubicin over doxorubicin. The additional analyses reported on January 8
provided hazard ratios for both the investigator-read scans and the central lab
scans.”
Levy further details the
design, outcome, and importance of the clinical trial before highlighting two
positive analyst actions on CytRx’s stock following the trial results. He also
outlines aldoxorubicin’s potential for the treatment of glioblastoma, the most
common and fatal form of brain cancer.
“It appears that all signs
are pointing to a company that is on the verge of giving hope to cancer
patients around the world. Patients often struggle with the decision to go
through the ordeal of cancer treatment, such as chemotherapy, because of the
painful side effects that can occur. CytRx may one day replace doxorubicin and
offer patients an alternative treatment that is not only more effective but
less harmful,” Levy concludes.
For more information, visit
www.CytRx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
